Literature DB >> 8945590

Nonopsonic binding of Mycobacterium tuberculosis to human complement receptor type 3 expressed in Chinese hamster ovary cells.

C Cywes1, N L Godenir, H C Hoppe, R R Scholle, L M Steyn, R E Kirsch, M R Ehlers.   

Abstract

Nonopsonic invasion of mononuclear phagocytes by Mycobacterium tuberculosis is likely important in the establishment of a primary infection in the lung. M. tuberculosis binds to a variety of phagocyte receptors, of which the mannose receptor and complement receptor type 3 (CR3) may support nonopsonic binding. CR3, a beta2 integrin, is a target for diverse intracellular pathogens, but its role in nonopsonic binding remains uncertain. We have examined the binding of M. tuberculosis H37Rv to human CR3 heterologously expressed in Chinese hamster ovary (CHO) cells, thereby circumventing the problems of competing receptors and endogenously synthesized complement, which are inherent in studies with mononuclear phagocytes. The surface expression of CD11b and CD18 was assessed by immunofluorescence, immunobead binding, flow cytometry, and immunoprecipitation with anti-CD11b and anti-CD18 monoclonal antibodies (MAbs). The functional activity of the surface-expressed CD11b/CD18 (CR3) heterodimer was confirmed by rosetting with C3bi-coated microspheres. We found that M. tuberculosis bound four- to fivefold more avidly to CR3-expressing CHO cells than to wild-type cells and, importantly, that this binding was at similar levels in the presence of fresh or heat-inactivated human or bovine serum or no serum. In contrast, Mycobacterium smegmatis bound poorly to CR3-expressing CHO cells in the absence of serum, but after opsonization in serum, binding was comparable to that of M. tuberculosis. The binding of M. tuberculosis to the transfected CHO cells was CR3 specific, as it was inhibited by anti-CR3 MAbs, particularly the anti-CD11b MAbs LM2/1 (I domain epitope) and OKM1 (C-terminal epitope), neither of which inhibit C3bi binding. MAb 2LPM19c, which recognizes the C3bi-binding site on CD11b, had little or no effect on M. tuberculosis binding. The converse was found for the binding of opsonized M. smegmatis, which was strongly inhibited by 2LPM19c but unaffected by LM2/1 or OKM1. CR3-specific binding was also evidenced by the failure of M. tuberculosis to bind to CHO cells transfected with an irrelevant surface protein (angiotensin-converting enzyme) in the presence or absence of serum. We conclude that the binding of M. tuberculosis H37Rv to CR3 expressed in CHO cells is predominantly nonopsonic and that the organism likely expresses a ligand that binds directly to CR3.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8945590      PMCID: PMC174532          DOI: 10.1128/iai.64.12.5373-5383.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Cloning of the beta subunit of the leukocyte adhesion proteins: homology to an extracellular matrix receptor defines a novel supergene family.

Authors:  T K Kishimoto; K O'Connor; A Lee; T M Roberts; T A Springer
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

2.  Human macrophage activation. Modulation of mannosyl, fucosyl receptor activity in vitro by lymphokines, gamma and alpha interferons, and dexamethasone.

Authors:  T Mokoena; S Gordon
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

3.  A semiquantitative rosetting assay for detection of cell-surface class I major histocompatibility complex molecules.

Authors:  L J Sigal; D E Wylie
Journal:  Biotechniques       Date:  1994-10       Impact factor: 1.993

4.  Surfactant protein a promotes attachment of Mycobacterium tuberculosis to alveolar macrophages during infection with human immunodeficiency virus.

Authors:  J F Downing; R Pasula; J R Wright; H L Twigg; W J Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

5.  Interaction of human monocytes, macrophages, and polymorphonuclear leukocytes with zymosan in vitro. Role of type 3 complement receptors and macrophage-derived complement.

Authors:  R A Ezekowitz; R B Sim; G G MacPherson; S Gordon
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

6.  Point mutations impairing cell surface expression of the common beta subunit (CD18) in a patient with leukocyte adhesion molecule (Leu-CAM) deficiency.

Authors:  M A Arnaout; N Dana; S K Gupta; D G Tenen; D M Fathallah
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

7.  Amino acid sequence of the alpha subunit of human leukocyte adhesion receptor Mo1 (complement receptor type 3).

Authors:  M A Arnaout; S K Gupta; M W Pierce; D G Tenen
Journal:  J Cell Biol       Date:  1988-06       Impact factor: 10.539

8.  Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum.

Authors:  J M Blackwell; R A Ezekowitz; M B Roberts; J Y Channon; R B Sim; S Gordon
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

9.  Macrophage type 3 complement receptors mediate serum-independent binding of Leishmania donovani. Detection of macrophage-derived complement on the parasite surface by immunoelectron microscopy.

Authors:  A O Wozencraft; G Sayers; J M Blackwell
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

10.  A peptide derived from the intercellular adhesion molecule-2 regulates the avidity of the leukocyte integrins CD11b/CD18 and CD11c/CD18.

Authors:  R Li; J Xie; C Kantor; V Koistinen; D C Altieri; P Nortamo; C G Gahmberg
Journal:  J Cell Biol       Date:  1995-05       Impact factor: 10.539

View more
  26 in total

1.  Nonopsonic binding of Mycobacterium tuberculosis to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent.

Authors:  C Cywes; H C Hoppe; M Daffé; M R Ehlers
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

2.  Role of complement receptors in uptake of Mycobacterium avium by macrophages in vivo: evidence from studies using CD18-deficient mice.

Authors:  L E Bermudez; J Goodman; M Petrofsky
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Generation of multinucleated giant cells in vitro by culture of human monocytes with Mycobacterium bovis BCG in combination with cytokine-containing supernatants.

Authors:  A Gasser; J Möst
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Macrophage receptors for Mycobacterium tuberculosis.

Authors:  J D Ernst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  Activation of human neutrophils by mycobacterial phenolic glycolipids.

Authors:  J Fäldt; C Dahlgren; A Karlsson; A M Ahmed; D E Minnikin; M Ridell
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

6.  Structures and interaction analyses of integrin αMβ2 cytoplasmic tails.

Authors:  Geok-Lin Chua; Xiao-Yan Tang; Monalisa Amalraj; Suet-Mien Tan; Surajit Bhattacharjya
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

7.  Role of CR4 in Mycobacterium tuberculosis-human macrophages binding and signal transduction in the absence of serum.

Authors:  Y Zaffran; L Zhang; J J Ellner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Diminished adherence and/or ingestion of virulent Mycobacterium tuberculosis by monocyte-derived macrophages from patients with tuberculosis.

Authors:  J Zabaleta; M Arias; J R Maya; L F García
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

9.  Mycobacterium leprae phenolglycolipid-1 expressed by engineered M. bovis BCG modulates early interaction with human phagocytes.

Authors:  Guillaume Tabouret; Catherine Astarie-Dequeker; Caroline Demangel; Wladimir Malaga; Patricia Constant; Aurélie Ray; Nadine Honoré; Nana Fatimath Bello; Esther Perez; Mamadou Daffé; Christophe Guilhot
Journal:  PLoS Pathog       Date:  2010-10-21       Impact factor: 6.823

10.  Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid.

Authors:  J Scott Ferguson; Jeremy J Weis; Jennifer L Martin; Larry S Schlesinger
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.